Search
Back

Ibrutinib

CAS 936563-96-1
Ibrutinib

General Information

Ibrutinib is an orally administered anticancer drug for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and Waldenstrm’s macroglobulinemia (WM ‘ also known as lymphoplasmacytic lymphoma).


About the API

Technology Synthetic
Therapeutic category Oncology
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

Updates About Ibrutinib

June 25, 2017
US DMF is available.

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.